Literature DB >> 32377006

REACH2: ruxolitinib for refractory aGvHD.

David Killock1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32377006     DOI: 10.1038/s41571-020-0385-z

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN: 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  1 in total

1.  Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease.

Authors:  Robert Zeiser; Nikolas von Bubnoff; Jason Butler; Mohamad Mohty; Dietger Niederwieser; Reuven Or; Jeff Szer; Eva M Wagner; Tsila Zuckerman; Bruyère Mahuzier; Judith Xu; Celine Wilke; Kunal K Gandhi; Gérard Socié
Journal:  N Engl J Med       Date:  2020-04-22       Impact factor: 91.245

  1 in total
  2 in total

1.  Ruxolitinib versus dexamethasone in hospitalized adults with COVID-19: multicenter matched cohort study.

Authors:  O V Stanevich; D S Fomina; I G Bakulin; S I Galeev; E A Bakin; V A Belash; A N Kulikov; A A Lebedeva; D A Lioznov; Yu S Polushin; I V Shlyk; E A Vorobyev; S V Vorobyeva; T V Surovceva; N V Bakulina; M A Lysenko; I S Moiseev
Journal:  BMC Infect Dis       Date:  2021-12-22       Impact factor: 3.090

2.  Efficacy and safety of ruxolitinib in steroid-refractory graft-versus-host disease: A meta-analysis.

Authors:  Shuang Fan; Wen-Xuan Huo; Yang Yang; Meng-Zhu Shen; Xiao-Dong Mo
Journal:  Front Immunol       Date:  2022-08-04       Impact factor: 8.786

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.